Imatinib mesylate (IM) is a selective and well-tolerated inhibitor of the BCR-ABL tyrosine kinase, and has significantly improved the prognosis of patients with chronic phase CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.